Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's flagship candidate, ACOG-100, seeks to improve cognitive function and tackle significant unmet needs among the aging demographic. With a robust proprietary neuroscience platform and a deep commitment to rigorous research and development, Alpha Cognition is well-positioned for growth as it advances its clinical pipeline and explores new therapeutic avenues. For institutional investors, the company presents a compelling opportunity to contribute to transformative patient care while capitalizing on the expanding healthcare sector.
| Revenue (TTM) | $10.83M |
| Gross Profit (TTM) | $9.47M |
| EBITDA | $-27.27M |
| Operating Margin | -229.10% |
| Return on Equity | -51.70% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.57 |
| Book Value | $2.64 |
| Price-to-Book | 3.25 |
| Price-to-Sales (TTM) | 16.92 |
| EV/Revenue | 12.86 |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 20.70% |
| Shares Outstanding | $21.77M |
| Float | $11.22M |
| % Insiders | 5.28% |
| % Institutions | 55.06% |
Volatility is currently expanding
Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a mult.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced the top-line results from its BEACON real-world study evaluating provider-reported cognitive, behavioral, functional, and tolerability outcomes among long-term care residents with mild to moderate Alzheimer's disease who were receiv.
Alpha Cognition Inc. (ACOG) Q1 2026 Earnings Call Transcript
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “The first quarter of 2026 marked our fourth full quarter of commercial operations for ZUNVEYL, the first new oral Alzheimer's treatment ap.
Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accom.
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACOG and any ticker you trade — then tracks every position and per-strategy win rate.
